Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin plus bevacizumab for diabetic macular edema
IRCT20190122042450N6Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin and bevacizumab in diabetic macular edema (DME) and type 2 diabetes mellitus (T2DM), sponsored by Iran University of Medical Sciences. Primary endpoint: Change in macular thickness. Started Mar 2022; status: completed.
02
Drugs
empagliflozinbevacizumab
03
Conditions
diabetic macular edema (DME)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20190122042450N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190122042450N6.